<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Genes &amp; Cells</journal-id><journal-title-group><journal-title xml:lang="en">Genes &amp; Cells</journal-title><trans-title-group xml:lang="ru"><trans-title>Гены и Клетки</trans-title></trans-title-group><trans-title-group xml:lang="zh"><trans-title>Genes and Cells</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2313-1829</issn><issn publication-format="electronic">2500-2562</issn><publisher><publisher-name xml:lang="en">Human Stem Cells Institute</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">643445</article-id><article-id pub-id-type="doi">10.17816/gc643445</article-id><article-id pub-id-type="edn">HUVIMO</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original Study Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные исследования</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Age-related immunophenotypic characteristics of perivascular mesenchymal stem cells in patients with heart defects</article-title><trans-title-group xml:lang="ru"><trans-title>Возрастные особенности иммунофенотипа мезенхимальных стволовых клеток периваскулярной жировой ткани у пациентов с пороками сердца</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0749-4093</contrib-id><contrib-id contrib-id-type="spin">2097-6785</contrib-id><name-alternatives><name xml:lang="en"><surname>Slesareva</surname><given-names>Tamara A.</given-names></name><name xml:lang="ru"><surname>Слесарева</surname><given-names>Тамара Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>soloveva081296@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-4321-8977</contrib-id><contrib-id contrib-id-type="spin">1539-5332</contrib-id><name-alternatives><name xml:lang="en"><surname>Uchasova</surname><given-names>Evgenia G.</given-names></name><name xml:lang="ru"><surname>Учасова</surname><given-names>Евгения Геннадьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p>
<p/></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>evg.uchasova@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6890-3287</contrib-id><contrib-id contrib-id-type="spin">2064-6262</contrib-id><name-alternatives><name xml:lang="en"><surname>Dyleva</surname><given-names>Yulia A.</given-names></name><name xml:lang="ru"><surname>Дылева</surname><given-names>Юлия Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>dyleva87@yandex.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0500-2449</contrib-id><contrib-id contrib-id-type="spin">8247-9881</contrib-id><name-alternatives><name xml:lang="en"><surname>Gorbatovskaya</surname><given-names>Evgeniya E.</given-names></name><name xml:lang="ru"><surname>Горбатовская</surname><given-names>Евгения Евгеньевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p>
<p/></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>eugenia.tarasowa@yandex.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-3996-3325</contrib-id><contrib-id contrib-id-type="spin">5705-9143</contrib-id><name-alternatives><name xml:lang="en"><surname>Belik</surname><given-names>Ekaterina V.</given-names></name><name xml:lang="ru"><surname>Белик</surname><given-names>Екатерина Владимировна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>sionina.ev@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4146-3373</contrib-id><contrib-id contrib-id-type="spin">9914-3705</contrib-id><name-alternatives><name xml:lang="en"><surname>Matveeva</surname><given-names>Vera G.</given-names></name><name xml:lang="ru"><surname>Матвеева</surname><given-names>Вера Геннадьевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>matveeva_vg@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-0683-991X</contrib-id><contrib-id contrib-id-type="spin">6326-3427</contrib-id><name-alternatives><name xml:lang="en"><surname>Torgunakova</surname><given-names>Evgeniya A.</given-names></name><name xml:lang="ru"><surname>Торгунакова</surname><given-names>Евгения Александровна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>tevgeniyatorgunakova@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2243-1621</contrib-id><contrib-id contrib-id-type="spin">4136-3280</contrib-id><name-alternatives><name xml:lang="en"><surname>Dvadtsatov</surname><given-names>Ivan V.</given-names></name><name xml:lang="ru"><surname>Двадцатов</surname><given-names>Иван Викторович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>dvadiv@kemcardio.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-0661-4076</contrib-id><contrib-id contrib-id-type="spin">4981-9218</contrib-id><name-alternatives><name xml:lang="en"><surname>Khalipulo</surname><given-names>Ivan K.</given-names></name><name xml:lang="ru"><surname>Халивопуло</surname><given-names>Иван Константинович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>halivopulo@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7992-645X</contrib-id><contrib-id contrib-id-type="spin">2969-2674</contrib-id><name-alternatives><name xml:lang="en"><surname>Tarasova</surname><given-names>Olga L.</given-names></name><name xml:lang="ru"><surname>Тарасова</surname><given-names>Ольга Леонидовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Cand. Sci. (Medicine)</p></bio><bio xml:lang="ru"><p>канд. мед. наук</p></bio><email>pathophysiology_kaf@mail.ru</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-7780-829X</contrib-id><contrib-id contrib-id-type="spin">4322-0963</contrib-id><name-alternatives><name xml:lang="en"><surname>Gruzdeva</surname><given-names>Olga V.</given-names></name><name xml:lang="ru"><surname>Груздева</surname><given-names>Ольга Викторовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>MD, Dr. Sci. (Medicine), Professor, Professor of the Russian Academy of Sciences</p>
<p/></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор, профессор РАН</p></bio><email>o_gruzdeva@mail.ru</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Research Institute for Complex Issues of Cardiovascular Diseases</institution></aff><aff><institution xml:lang="ru">Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Kemerovo State Medical University</institution></aff><aff><institution xml:lang="ru">Кемеровский государственный медицинский университет</institution></aff></aff-alternatives><pub-date date-type="preprint" iso-8601-date="2025-06-22" publication-format="electronic"><day>22</day><month>06</month><year>2025</year></pub-date><pub-date date-type="pub" iso-8601-date="2025-07-23" publication-format="electronic"><day>23</day><month>07</month><year>2025</year></pub-date><volume>20</volume><issue>2</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>141</fpage><lpage>151</lpage><history><date date-type="received" iso-8601-date="2024-12-26"><day>26</day><month>12</month><year>2024</year></date><date date-type="accepted" iso-8601-date="2025-05-29"><day>29</day><month>05</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2025, Eco-Vector</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2025, Эко-Вектор</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="en">Eco-Vector</copyright-holder><copyright-holder xml:lang="ru">Эко-Вектор</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2028-07-23"/></permissions><self-uri xlink:href="https://genescells.ru/2313-1829/article/view/643445">https://genescells.ru/2313-1829/article/view/643445</self-uri><abstract xml:lang="en"><p><bold>BACKGROUND:</bold> Currently, there are only a few studies evaluating the role of perivascular mesenchymal stem cells in the pathogenesis of cardiovascular diseases. Heart defects are a broad category of conditions affecting people of all ages. Therefore, biological characteristics of perivascular mesenchymal stem cells may be relevant to this area of research. The expression profile of surface markers is a key characteristic of cells that represents their functional state. This work evaluated and compared immunophenotypic characteristics of perivascular mesenchymal stem cells obtained from patients of different ages with heart defects of various non-inflammatory origins.</p> <p><bold>AIM:</bold> The study aimed to evaluate morphotypes and immunophenotypes of perivascular mesenchymal stem cells in pediatric and elderly patients with heart defects of various origins.</p> <p><bold>METHODS:</bold> The study included 16 patients of various ages with heart defects. Mesenchymal stem cells were isolated from perivascular adipose tissue and cultured. The levels of the following surface markers expressed by these cells were evaluated using flow cytofluorimetry for passages 2–4: CD90, CD105, CD73, CD34, and HLA-DR.</p> <p><bold>RESULTS:</bold> Only 47.97% of the cells in passage 2 in the pediatric group expressed specific surface markers. However, the number of cells showing a perivascular mesenchymal stem cell phenotype increased with each further passage (<italic>p</italic> = 0.0016). The subcultivation of perivascular mesenchymal stem cells obtained from older patients revealed that, in passage 2, 95.98% of the cells had specific surface markers, which decreased to 44.59% by passage 4 (<italic>p</italic> = 0.0016).</p> <p><bold>CONCLUSION:</bold> The expression of the study surface markers (CD90, CD105, CD73, CD34, HLA-DR) was less significant in perivascular mesenchymal stem cells obtained from older patients with non-inflammatory heart defects than in cells obtained from children with similar defects.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Обоснование.</bold> На сегодняшний день имеется ограниченное количество исследований, раскрывающих роль мезенхимальных стволовых клеток (МСК) периваскулярной жировой ткани (ПВЖТ) в патогенезе сердечно-сосудистых заболеваний, в частности пороков сердца, которым подвержены люди всех возрастов. В связи с этим представляет интерес изучение биологических особенностей МСК ПВЖТ при данной патологии. Профиль экспрессии поверхностных маркёров является базовой характеристикой клеток, которая отражает их функциональное состояние, поэтому данная работа посвящена оценке и сравнительной характеристике иммунофенотипа МСК ПВЖТ, полученных от пациентов разных возрастов с пороками сердца различной невоспалительной этиологии.</p> <p><bold>Цель.</bold> Изучение морфотипа и иммунофенотипа МСК ПВЖТ у пациентов детского и пожилого возраста с пороками сердца разной этиологии.</p> <p><bold>Методы.</bold> В исследование было включено 16 пациентов с пороками сердца разных возрастных групп. Из ПВЖТ выделяли МСК и культивировали их. Со 2-го по 4-й пассаж проводили исследование уровня экспрессии данными клетками поверхностных маркёров СD90, CD105, CD73, CD34 и HLA-DR методом проточной цитофлуориметории.</p> <p><bold>Результаты.</bold> В культуре МСК, полученной из ПВЖТ пациентов детского возраста, на 2-м пассаже лишь 47,97% клеток экспрессировали специфические поверхностные маркёры. Однако с увеличением количества пассажей число клеток с фенотипом, характерным для МСК, повышалось (<italic>р</italic>=0,0016). При пассировании МСК ПВЖТ пациентов старшего возраста обнаружено, что на втором пассаже 95,98% клеток несли на своей поверхности специфические маркёры, экспрессия которых уменьшалась по мере пассирования и к 4-му пассажу снизилась до 44,59% (<italic>р</italic>=0,0016).</p> <p><bold>Заключение.</bold> Изучаемые поверхностные маркёры (СD90, CD105, CD73, CD34 и HLA-DR) экспрессировались в МСК ПВЖТ пациентов старшего возраста с пороками сердца невоспалительной этиологии слабее, чем в МСК ПВЖТ, полученных от детей со схожей патологией сердца.</p></trans-abstract><kwd-group xml:lang="en"><kwd>mesenchymal stem cells</kwd><kwd>adipose tissue</kwd><kwd>heart defect</kwd><kwd>immunophenotyping</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>мезенхимальные стволовые клетки</kwd><kwd>жировая ткань</kwd><kwd>порок сердца</kwd><kwd>иммунофенотип</kwd></kwd-group><funding-group><funding-statement xml:lang="en">The article is part of the basic research project of the Research Institute for Complex Issues of Cardiovascular Diseases (Project No. 0419-2022-0002 “Development of Innovative Models for Managing Risk Factors for Cardiovascular and Concomitant Diseases Based on the Study of Fundamental, Clinical, and Epidemiological Mechanisms and Methods of Healthcare Management in the Industrial Region of Siberia”).</funding-statement><funding-statement xml:lang="ru">Статья подготовлена в рамках проекта фундаментальных исследований ФГБНУ «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний» № 0419-2022-0002 «Разработка инновационных моделей управления риском развития болезней системы кровообращения с учетом коморбидности на основе изучения фундаментальных, клинических, эпидемиологических механизмов и организационных технологий медицинской помощи в условиях промышленного региона Сибири».</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Grigoras A, Amalinei C, Balan RA, et al. Perivascular adipose tissue in cardiovascular diseases — an update. Anatol J Cardiol. 2019;22(5):219–231. doi: 10.14744/AnatolJCardiol.2019.91380</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Gollasch M. Adipose-vascular coupling and potential therapeutics. Annu Rev Pharmacol Toxicol. 2017;57:417–436. doi: 10.1146/annurev-pharmtox-010716-104542</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Henrichot E, Juge-Aubry CE, Pernin A, et al. Production of chemokines by perivascular adipose tissue: a role in the pathogenesis of atherosclerosis? Arterioscler Thromb Vasc Biol. 2005;25(12):2594–2599. doi: 10.1161/01.ATV.0000188508.40052.35</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Gil-Ortega M, Somoza B, Huang Y, et al. Regional differences in perivascular adipose tissue impacting vascular homeostasis. Trends Endocrinol Metab. 2015;26(7):367–375. doi: 10.1016/j.tem.2015.04.003</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Cai M, Zhao D, Han X, et al. The role of perivascular adipose tissue-secreted adipocytokines in cardiovascular disease. Front Immunol. 2023;14:1271051. doi: 10.3389/fimmu.2023.1271051 EDN: RHPDXK</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Crisan M, Yap S, Casteilla L, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. Cell Stem Cell. 2008;3(3):301–313. doi: 10.1016/j.stem.2008.07.003 EDN: LUIGDV</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Lin G, Garcia M, Ning H, et al. Defining stem and progenitor cells within adipose tissue. Stem Cells and Development. 2008;17(6):1053–1063. doi: 10.1089/scd.2008.0117</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Boytsov SA, Drapkina OM, Shlyakhto EV, et al. Epidemiology of cardiovascular diseases and their risk factors in regions of Russian Federation (ESSE-RF) Study. Ten years later. Cardiovascular Therapy and Prevention. 2021;20(5):143–152. doi: 10.15829/1728-8800-2021-3007 EDN: ZPGROP</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Truong NC, Bui KH, Van Pham P. Characterization of senescence of human adipose-derived stem cells after long-term expansion. Adv Exp Med Biol. 2019;1084:109–128. doi: 10.1007/5584_2018_235 EDN: JECGGK</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Zhou S, Greenberger JS, Epperly MW, et al. Age-related intrinsic changes in human bone-marrow-derived mesenchymal stem cells and their differentiation to osteoblasts. Aging Cell. 2008;7(3):335–343. doi: 10.1111/j.1474-9726.2008.00377.x</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Li K, Shi G, Lei X, et al. Age-related alteration in characteristics, function, and transcription features of ADSCs. Stem Cell Res Ther. 2021;12(1):473. doi: 10.1186/s13287-021-02509-0 EDN: RZTHIQ</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Tan L, Liu X, Dou H, Hou Y. Characteristics and regulation of mesenchymal stem cell plasticity by the microenvironment — specific factors involved in the regulation of MSC plasticity. Genes Dis. 2020;9(2):296–309. doi: 10.1016/j.gendis.2020.10.006 EDN: CPEQLJ</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Yu B, Wang X, Song Y, et al. The role of hypoxia-inducible factors in cardiovascular diseases. Pharmacol Ther. 2022;238:108186. doi: 10.1016/j.pharmthera.2022.108186 EDN: KTZRGE</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315–317. doi: 10.1080/14653240600855905</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Costa LA, Eiro N, Fraile M, et al. Functional heterogeneity of mesenchymal stem cells from natural niches to culture conditions: implications for further clinical uses. Cell Mol Life Sci. 2021;78(2):447–467. doi: 10.1007/s00018-020-03600-0 EDN: MDGGAJ</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Sibov TT, Severino P, Marti LC, et al. Mesenchymal stem cells from umbilical cord blood: parameters for isolation, characterization and adipogenic differentiation. Cytotechnology. 2012;64(5):511–521. doi: 10.1007/s10616-012-9428-3 EDN: RNYGNV</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Moraes DA, Sibov TT, Pavon LF, et al. A reduction in CD90 (THY-1) expression results in increased differentiation of mesenchymal stromal cells. Stem Cell Res Ther. 2016;7(1):97. doi: 10.1186/s13287-016-0359-3 EDN: CTMQAQ</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Zhu H, Mitsuhashi N, Klein A, et al. The role of the hyaluronan receptor CD44 in mesenchymal stem cell migration in the extracellular matrix. Stem Cells. 2006;24(4):928–935. doi: 10.1634/stemcells.2005-0186</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Jaganathan BG, Kumar A, Bhattacharyya J. CD90 expression in mesenchymal stem cells of the malignant niche. Experimental Hematology. 2015;43(9):S69. doi: 10.1016/j.exphem.2015.06.150</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Massaro F, Corrillon F, Stamatopoulos B, et al. Age-related changes in human bone marrow mesenchymal stromal cells: morphology, gene expression profile, immunomodulatory activity and miRNA expression. Front Immunol. 2023;14:1267550. doi: 10.3389/fimmu.2023.1267550 EDN: HBYSDN</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Levi B, Wan DC, Glotzbach JP, et al. CD105 protein depletion enhances human adipose-derived stromal cell osteogenesis through reduction of transforming growth factor β1 (TGF-β1) signaling. J Biol Chem. 2011;286(45):39497–39509. doi: 10.1074/jbc.M111.256529</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Petinati N, Kapranov N, Davydova Y, et al. Immunophenotypic characteristics of multipotent mesenchymal stromal cells that affect the efficacy of their use in the prevention of acute graft vs host disease. World J Stem Cells. 2020;12(11):1377–1395. doi: 10.4252/wjsc.v12.i11.1377 EDN: DOJDDV</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Wang X, Chen X, Xia D, et al. Adipose tissue hypoxia caused by cyanotic congenital heart disease and its impact on adipokine dysregulation. Int J Clin Exp Pathol. 2016;9(9):9148–9156.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Minor M, Alcedo KP, Battaglia RA, Snider NT. Cell type- and tissue-specific functions of ecto-5’-nucleotidase (CD73). Am J Physiol Cell Physiol. 2019;317(6):C1079–C1092. doi: 10.1152/ajpcell.00285.2019 EDN: EXURLC</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Semenova E, Grudniak MP, Machaj EK, et al. Mesenchymal stromal cells from different parts of umbilical cord: approach to comparison &amp; characteristics. Stem Cell Rev Rep. 2021;17(5):1780–1795. doi: 10.1007/s12015-021-10157-3 EDN: OVMHWE</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Kimura K, Breitbach M, Schildberg FA, et al. Bone marrow CD73+ mesenchymal stem cells display increased stemness in vitro and promote fracture healing in vivo. Bone Rep. 2021;15:101133. doi: 10.1016/j.bonr.2021.101133 EDN: NPGHSR</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Stenderup K, Justesen J, Clausen C, Kassem M. Aging is associated with decreased maximal life span and accelerated senescence of bone marrow stromal cells. Bone. 2003;33(6):919–926. doi: 10.1016/j.bone.2003.07.005 EDN: EUOPSV</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Mareschi K, Ferrero I, Rustichelli D, et al. Expansion of mesenchymal stem cells isolated from pediatric and adult donor bone marrow. J Cell Biochem. 2006;97(4):744–754. doi: 10.1002/jcb.20681</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Saperova EV, Vahlova IV. Congenital heart diseases in children: incidence, risk factors, mortality. Current Pediatrics (Moscow). 2017;16(2):126–133. doi: 10.15690/vsp.v16i2.1713 EDN: YRGVRT</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Adan A, Eleyan L, Zaidi M, et al. Ventricular septal defect: diagnosis and treatments in the neonates: a systematic review. Cardiol Young. 2021;31(5):756–761. doi: 10.1017/S1047951120004576 EDN: BVRMFA</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Ladich E, Nakano M, Carter-Monroe N, Virmani R. Pathology of calcific aortic stenosis. Future Cardiol. 2011;7(5):629–642. doi: 10.2217/fca.11.53</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Aizenstadt AA, Enukashvili NI, Zolina TN, et al. Comparison of proliferation and immunophenotype of msc, obtainedfrom bone marrow, adipose tissue and umbilical cord. Herald of North-Western State Medical University Named After I.I. Mechnikov. 2015;7(2):14–22. EDN: UZAGDP</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Jones DL, Wagers AJ. No place like home: anatomy and function of the stem cell niche. Nat Rev Mol Cell Biol. 2008;9(1):11–21. doi: 10.1038/nrm2319</mixed-citation></ref></ref-list></back></article>
